Bacillus Coagulans

SNZ 1969Our FDA GRAS approved flagship strain: Bacillus coagulans SNZ 1969™ is unique in the space of spore forming probiotic strains. It boasts an exceptional history of use, stability profile, research and genetic pedigree. Combined with Sanzyme’s experience in end-to-end production and decades of continuous technological improvement, SNZ 1969™ is a reliable, long term choice for inclusion in probiotic formulations in supplements, food, and pharmaceuticals.

Pedigree

  • The technology for the production of SNZ 1969 and the mother culture was transferred via technology transfer by Sankyo Japan in 1972
  • Strain was isolated from green malt and is a sister strain to the original Nakamura strain

History of Use

  • SNZ 1969™ was produced and used by Sanzyme (then known as Uni-Sankyo) as the active ingredient in SPORLAC™, a pharmaceutical drug sold in the Indian pediatric market
  • SPORLAC™ was launched in 1972 and is still being sold. It is the first probiotic to be sold in India and is still a market leader
  • Over the years, products have been launched within the SPORLAC™ umbrella incluvding SPORLAC DS™, and SPORLAC PLUS™
  • Over four decades in the Indian pharmaceutical market, there have been no reported serious adverse effects
  • Unprecedented history of safe use: More than 2 Billion doses prescribed to infants, children, adults and elderly since 1992
Rectangle 10

End to End Production in a Dedicated Facility

  • Sanzyme Biologics manages all inputs, and process parameters at all stages of probiotic production: from flasks to seed fermenters to full scale fermentation to blending and spray drying.
  • Due to our years of experience in production of Bacillus coagulans, Sanzyme has made constant incremental improvements to the inputs used and production. The result is a healthier spore, and we test this against our stringent assay method.

Proven Stability in a
variety of dosage forms

  • Capsules
  • Sachets
  • Tablets
  • Candy
  • Gummies
  • Powders
  • Chocolates

Clinical REFERENCES

DIGESTION
DIARRHEA
  1. Clinical trial of Sporlac in gastroenteritis. 1999
    Ronald Ross Institute of Tropical Diseases, Hyderabad.
  2. Randomised controlled clinical trial of Lactobacillus sporogenes (Bacillus coagulans), used as probiotic in clinical practice, on acute watery diarrhea in children.
    Dutta P et al., Tropical Medicine and International Health 2011; volume 16 no 5, pp 555– 561.
  3. Effect of Lactobacillus on the incidence and severity of acute rotavirus diarrhea in infants.
    A prospective placebo-controlled double-blind study
    Chandra R.K., Nutrition Research 2002; 22: 65–69
  4. Sporlac in neonatal diarrhea
    Dhongade R. K. and Anjaneyulu R., Maharashtra Medical Journal 1977; XXIII (II): 473
INFANTS AND CHILDREN
INFANTILE DIARRHEA
  1. Effect of Lactobacillus on the incidence and severity of acute rotavirus diarrhea in infants.
    A prospective placebo-controlled double-blind study
    Chandra R.K., Nutrition Research 2002; 22: 65–69
  2. Sporlac in neonatal diarrhea
    Dhongade R. K. and Anjaneyulu R., Maharashtra Medical Journal 1977; XXIII (II): 473
IMMUNITY
IMMUNITY
  1. A Study showing antagonistic effect of Lactobacilli casei and Lactobacilli sporogenesis against some common pathogens- in vitro.
    Shukla P. and Sharma J., Int. J. Curr. Microbiol. App. Sci 2015; 4(6): 36-40
  2. A study on the antibiotic susceptibilities of some probiotic strains used as the dietary supplements.
    Sharma J. and Shukla P., International Journal of Institutional Pharmacy and Life Sciences 2015; 5(5): September-October
  3. Immunomodulatory activity of Lactobacillus sporogenes.
    BABAR V., THOMAS R., BHASKAR M., International Journal of Therapeutic Applications 2012; Volume 3: 32 – 38
  4. Evaluating antimicrobial activity of common commercial Probiotic Products against Staphylococcus aureus

    Sharma J. and Goyal A., Indian Res. J. Genet. & Biotech 2017; 9(2) May: 272 – 278

WOMENS HEALTH
VAGINITIS
  1. A Study showing antagonistic effect of Lactobacilli casei and Lactobacilli sporogenesis against some common pathogens- in vitro.
    Shukla P. and Sharma J., Int. J. Curr. Microbiol. App. Sci 2015; 4(6): 36-40
ORAL HEALTH
MOUTH ULCERATION (APTHOUS STOMATITIS)
  1. Clinical trial of Sporlac in the treatment of recurrent Apthous ulceration
    Sharma J. K. et al., U.P. State Dental Journal 1980; Vol 11 January: 7-12
GUMS
  1. A comparative evaluation of probiotics on salivary mutans streptococci counts in Indian children
    Jindal G et al., European Archives of Paediatric Dentistry 2011; 12: Issue 4
HEART HEALTH
CHOLESTEROL
  1. Preliminary observations on effect of Lactobacllus sporogenes on serum lipid levels in hypercholerolemic patients
    Mohan J. C. et al., Indian J Med Res (B) 1990; Vol 92 December: 431-432.